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Aspirin enhances opsonophagocytosis and is
associated to a lower risk for Klebsiella
pneumoniae invasive syndrome
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Abstract
Background: Klebsiella pneumoniae (KP) expressing hypermucoviscosity phenotype (HV-KP) has abundant capsular
polysaccharide (CPS) and is capable of causing invasive syndrome. Sodium salicylate (SAL) reduces the production
of CPS. The study was aimed to investigate the relationship between aspirin usage and KP-mediated invasive
syndrome and the effect of SAL on HV-KP.
Methods: Patients with community-acquired KP bacteraemia were prospectively enrolled. KP-M1, a serotype-K1
HV-KP clinical isolate, was used in the following experiments: CPS production, HV-KP phenotype, and the effect of
SAL on neutrophils phagocytosis. The effect of oral aspirin intake on the leukocyte bactericidal activity was evaluated.
Results: Patients infected by HV-KP and diabetic patients with poor glycemic control were at an increased risk for invasive
syndrome (p < 0.01); those who had recent use of aspirin (p = 0.02) were at a lower risk. CPS production was significantly
reduced in the presence of SAL. The HV-KP phenotype and resistance to neutrophil phagocytosis were both significantly
reduced in the KP-M1 after incubation with SAL (p< 0.01). Aspirin treatment significantly enhanced the killing of KP-M1
by leukocytes (p < 0.01).
Conclusion: Treatment with SAL significantly reduces CPS production in HV-KP, thereby contributing to leukocyte
phagocytosis and bactericidal activity against this pathogen.
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Background
Primary Klebsiella pneumoniae (KP) liver abscess occurs
most often in patients with type 2 diabetic mellitus
(DM), and can present with the following metastatic
complications: bacteraemia, meningitis, endophthalmitis,
and necrotising fasciitis [1,2]. Glistening mucoid colonies
with a viscid consistency are usually formed by KP that
are cultured on agar media [1-3]. Hypermucoviscous KP
(HV-KP) causes a unique constellation of symptoms, and is
associated with the development of invasive syndrome
[2,3]. The HV-KP strain is resistant to phagocytosis by neu-
trophils, an important characteristic that may contribute to
the dissemination of infection [4-6]. The capsular polysac-
charide (CPS) contributes to the mucoid phenotype, and
has been identified as a determinant of KP infection, sug-
gesting that CPS plays a role in the development of invasive
syndrome [7,8]. CPS also has been used to develop a sero-
typing system for KP isolates, and currently 77 capsular se-
rotypes have been identified. Compared to those belonged
to non-K1 serotypes, isolates of the serotype K1 were signifi-
cantly more virulent and more likely to be associated with
KP-mediated invasive syndrome [2,7].
Chemotherapeutic agents that reduce CPS production
may be effective as an adjunct therapy for HV-KP infec-
tion. Therapeutically safe concentrations of sodium sali-
cylate (SAL), the major metabolite of aspirin, can reduce
CPS production by up to 70% [9,10]. Aspirin also re-
duces the synthesis of prostaglandins (PGs) by inhibiting
cyclooxygenase (COX)-mediated arachidonic acid me-
tabolism [11], and therefore has attracted attention as a
means of facilitating the killing of bacteria by leukocytes
[12,13]. We hypothesized that SAL may enhance the
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phagocytosis of HV-KP by leukocytes as a result of re-
duced CPS production. In the present study, we tried to
examine this hypothesis by investigating the effect of
SAL on bacterial survival, hypermucoviscosity, CPS pro-
duction, leukocyte phagocytosis, and bactericidal activity
against HV-KP. Furthermore, we conducted a prospect-
ive study to evaluate the relationship between aspirin
usage and KP-mediated invasive syndrome.
Methods
Ethics statement
All the protocols used in the present study have been ap-
proved by the Institutional Review Board at Kaohsiung
Chang Gung Memorial Hospital (KCGMH; approval nos.
97-0599B and 100-0629B). Informed consent was not re-
quired in participants because of the observational nature
of the study (97-0599B). In addition, 5 healthy male volun-
teers provided their written informed consents to partici-
pate in the study (100-0629B).
Study design and participants
In this prospective study, patients who were admitted to
the KCGMH between January 1, 2008, and December 31,
2010, with community-acquired mono-microbial bacter-
aemia caused by KP were enrolled for the investigation of
risk factors for KP-mediated invasive syndrome. Only the
KP isolates from the participants’ first blood collection were
used in this study. Peripheral blood samples were also col-
lected from 5 healthy male volunteers aged between 25 and
40 years old and used in the leukocyte phagocytosis and
bactericidal activity assays as described below.
The diagnosis of KP-mediated invasive syndrome was
made when the criteria for sepsis were met [14] plus the
presence of at least one of the following infections: liver
abscess, meningitis, empyema, mycotic aneurysm, necro-
tising fasciitis or endophthalmitis [15]. To investigate
the risk factors of KP-mediated invasive syndrome, the
following clinical variables were assessed: age, sex, co-
morbidities (including DM, liver cirrhosis, malignancy,
chronic renal failure, and biliary tract disease), and a his-
tory of receiving proton-pump inhibitors or aspirin or
antibiotics in the previous month prior to the collection
of their first KP-positive blood culture. To monitor the
glycemic control [16], the hemoglobin A1c (HbA1c) was
checked when diabetic patients were enrolled in this
study. Controls were retrieved from a computer-aided
selection of eligible individuals who community onset
bacteremia caused by other than KP. Each subject was
age-matched, and the ratio of case of KP invasive syn-
drome to control patients was 1:1.
Reagents
We purchased 10 mg/mL SAL, 50 mM ethylenedi-
amine tetra-acetic acid, and 25 mM ethylene-bis
(oxyethylenenitrile) tetra-acetic acid from Sigma-Aldrich
(St. Louis, MO). All stock solutions were prepared in deion-
ized water, brought to pH 7.5 using 10 N NaOH, and filter
sterilized. Trypticase soy agar (TSA) and broth (TSB) media
(Becton Dickinson, Franklin Lakes, NJ) were used for bac-
terial cultures. In some experiments, various concentrations
of SAL were added into the growth media as indicated in
the following experiments. The pH of the growth media
with and without SAL was not significantly different.
Bacterial isolates, hypermucoviscosity phenotype,
and serotype determination
All KP isolates were identified using standard methods. The
HV phenotype was identified using a modified string test
[17], with a viscous string longer than 10 mm as the criteria
for a positive result. K1 serotyping was assessed by polymer-
ase chain reaction and capsular swelling technique [1]. A
KP-M1 (serotype K1) strain was isolated from an enrolled
patient with invasive syndrome presenting as liver abscess
and endophthalmitis and was used as the representing
strain in the following experiments.
Effects of SAL on live KP
To exclude the possibility that SAL possesses direct bac-
tericidal properties against KP, broth cultures of KP-M1
were incubated in the presence of various concentrations
(0, 10, 30 and 300 μg/mL) of SAL. After 2, 4, 8, 10, 12,
and 24 hours, the number of surviving bacteria was
monitored by reading the absorbance at 490 nm. We
further investigated the SAL effect on the hypermucov-
iscosity of KP. The KP-M1 colonies were cultured in
plate media containing 0, 10, or 30 μg/mL of SAL, re-
spectively, and incubated overnight at 37°C. The length
of the mucoviscous string was measured [17].
Quantification of CPS
The CPS concentration was determined by a modified
carbazole assay for uronic acid (UA) [18] after total CPS
was quantitatively extracted from whole bacterial cul-
tures [19]. A 0.5-mL sample was mixed with 3 mL of
0.025 M sodium tetraborate (VWR, Radnor, PA) in sul-
furic acid, and heated at 100°C for 10 min. After cooling,
0.1 mL of 0.125% carbazole (Sigma-Aldrich, St. Louis,
MO) in absolute ethanol was added, and the samples
were heated for another 15 min. The absorbance of the
sample at 530 nm was measured, and the concentration
of UA was extrapolated from a standard curve that was
constructed using glucuronolactone (Sigma-Aldrich, St.
Louis, MO) standards. To quantify CPS after SAL treat-
ment, bacterial colonies were cultured in media containing
0, 10, or 30 μg/mL SAL and incubated overnight at 37°C.
All samples were assayed at least 3 times. The quantities of
CPS detected were expressed as micrograms of UA per
1011 colony forming units (μg UA/ 1011 cfu).
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Flow cytometric analysis of leukocyte phagocytosis
The KP-M1 bacteria were cultured overnight at 37°C on
TSA media containing 0, 10, or 30 μg/mL SAL. The
bacterial colonies were irradiated with ultraviolet light
then were sub-cultured in plate to confirm sterile after
overnight incubation. The irradiated cultures were resus-
pended in carbonate buffer containing 0.1% fluorescein
isothiocyanate (FITC). The FITC-stained KP (FITC-KP)
cells were counted using a bacterial cytometer and a
fluorescence microscope. The FITC-KP cells were analyzed
using a FACS Calibur flow cytometer (BD Biosciences, San
Jose, CA) to verify that bacterial staining was uniform
throughout each sample.
Phagocytosis was measured using a standard assay [20].
Neutrophil suspensions and pooled human sera were col-
lected from healthy human volunteers. The neutrophil sus-
pension was adjusted to contain 1 × 106 cells in 100 μL PBS
and was then combined with 600 μL PBS and 100 μL
pooled human serum (10% v/v opsonization). Multiple vol-
umes of 200 μL of FITC-KP cells containing approximately
4 × 107 cfu/mL were added to 800 μL of the neutrophil-
containing PBS to produce a final volume of 1.0 mL at a
multiplicity of infection of 10:1. Each tube was incubated in
a shaking water bath at 37°C for 60 min. Ethidium bromide
was added to suppress extracellular fluorescence. A FACS-
can instrument (BD Biosciences, San Jose, CA) was used to
detect FITC fluorescence at 488 nm, and 2 × 104 cells were
processed using the Cellquest version 1.0 software (BD
Biosciences, San Jose, CA). By assessing phagocytosis of un-
stained and FITC-stained bacteria, the boundary of positive
and negative fluorescence was established, and the percent-
age of ingested bacteria was determined.
Ex vivo human leukocyte bactericidal activity assay
Bactericidal activity was measured using a standard assay
method [21]. The KP-M1 organisms were cultured on
TSA media containing 0 or 30 μg/mL SAL, respectively,
and incubated overnight at 37°C. The KP-M1 organisms
were opsonized by the addition of 10% pooled human
serum collected from 5 healthy male volunteers who did
not take any aspirin prior to the donation. The suspen-
sion was mixed at a multiplicity of infection of 10:1 to
whole blood leukocytes, which had been collected from
volunteers either before or one hour after a 100-mg oral
dose of aspirin. Samples were collected one hour later,
and diluted in H2O (pH 11.0, adjusted by NaOH) to lyse
the leukocytes and disperse the bacteria for the power-
plate colony assay [22]. All tests were performed in trip-
licate to ensure reproducibility.
Statistical analysis
The categorical variables were compared using the
chi-square test or the Fisher exact test, as appropriate.
A multivariate logistic regression model was used to
evaluate risk factors for invasive syndrome by calculat-
ing the odds ratio (OR) and 95% confidence interval
(CI) of each clinical variable. All experimental data
were expressed as the mean ± standard deviation. Differ-
ences among the results of the string test (mm) and phago-
cytosis (gate %) were analyzed using the Mann-Whitney
U-test. The counts of surviving bacteria were analyzed
using the log rank test. All statistical analyses were two-
sided, and a p value less than 0.05 was considered to indi-
cate a statistically significant result.
Results
Risk factors for KP-mediated invasive syndrome
Of the 408 patients with community-acquired mono-KP
bacteremia, 76 (18.6%) had invasive syndrome. Based on
results of the modified string test, the HV phenotype
was identified in 147 (36.0%) isolates. As demonstrated
in Table 1, invasive syndrome occurred more often in
HV-KP-infected patients (p < 0.01). A large proportion
(75, 42.9%) of the patients studied also suffered from
DM. The proportion of KP infection-related invasive
syndrome was significantly higher among these DM pa-
tients (p = 0.04), especially those with poor glycemic
control (HbA1c ≥ 9%; p < 0.01). Aspirin therapy received
during the month prior to the diagnosis of the KP infec-
tion was found in 58 (14.2%) patients, and they were less
likely to develop invasive syndrome (p < 0.01; Table 1).
Further multivariate analysis indicated that community-
acquired KP-bacteremic patients who were infected by
strains expressing the HV phenotype (odds ratio [OR],
31.07; 95% confidence interval [CI], 13.55-71.22; p <
0.01) and DM patients with poor glycemic control (OR,
2.46; 95% CI, 1.27-4.77; p < 0.01) were at increased risk,
whereas those who had a recent use of aspirin (OR, 0.17;
95% CI, 0.04-0.79; p = 0.02) were at a lower risk of ac-
quiring KP-associated invasive syndrome. Comparing
with age-matched control group (Table 1), it revealed
that patients with KP-associated invasive syndrome were
more likely to have DM (p = 0.01), DM with poor gly-
cemic control (p = 0.02) and less likely to have malig-
nancy (p < 0.01).
Effects of SAL on live KP
No significant difference was found between the number
of viable KP-M1 cells cultured with or without the pres-
ence of various concentrations of SAL. However, com-
pared to those grown in other concentrations of SAL,
viable KP-M1 cells were much less in 300 μg/mL of
SAL (Figure 1). It suggests that at high concentration of
SAL (300 μg/mL) might interfere with some cellular
processes or bind to essential elements, which results in
reduction in growth.
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Effect of SAL on hypermucoviscosity and CPS production
Incubation of KP-M1 colonies on TSB agar media con-
taining 10 or 30 μg/mL SAL significantly decreased the
incidence of the HV phenotype, according to the results
of the modified string test (p < 0.01, Figure 2A and 2B). The
quantity of CPS found in KP-M1 cells was equivalent to
2475.87 ± 175.09 μg UA/1011 cfu. When the KP-M1 bac-
teria were cultured in 10 or 30 μg/mL SAL, the quantity of
CPS decreased to 1821.27 ± 73.76 μg UA/1011 cfu and
1574.48 ± 86.90 μg UA/1011 cfu, respectively. This equaled
to 26.4% (p < 0.01) and 34.4% (p < 0.01) reduction of CPS
levels, respectively, as compared with the mean control
values. Therefore, the quantity of CPS could be significantly
reduced in the presence of SAL.
Effects of SAL on leukocyte phagocytosis and ex vivo
leukocyte bactericidal activity
The difference between the rate of KP-M1 phagocytosis
by neutrophils before and after co-incubation with 10 or
30 μg/mL SAL was significant (p < 0.01; Figure 3A and
3B). The KP-M1 was significantly more susceptible to
phagocytosis after incubation with 10 or 30 μg/mL SAL.
The ex vivo bactericidal activity of leukocytes from
healthy volunteers that were collected one hour follow-
ing the oral administration of 100 mg of aspirin was
significantly greater than that of leukocytes collected
from the same volunteers before the aspirin treatment
(p < 0.01; Figure 4). The results indicated that aspirin
was able to enhance significantly the whole blood
leukocyte bacterial killing despite the pre-incubation of
KP-M1 with SAL.
Table 1 Comparisons of differences between patients with community-acquired K. pneumoniae bacteremia and
control group
Community-acquired K. pneumoniae bacteremia
Variable Invasive syndrome (%)
Yes (n = 76) No (n = 332) p value Control (%) (n = 76) p value+
Hypermucoviscosity phenotype of K. pneumoniae 69 (90.8) 78 (23.5) < 0.01*
Male 40 (52.6) 150 (45.2) 0.25 40 (52.6) 0.99
Age ≥ 60 yrs 39 (51.3) 128 (38.6) 0.05 39 (51.3) 0.99
Diabetes mellitus (DM) 41 (53.9) 134 (40.4) 0.04 25 (32.9) 0.01
DM with poor glycemic control (HbA1c ≥ 9%) 32 (42.1) 75 (22.6) < 0.01* 17 (22.4) 0.02
Cardiovascular diseases 17 (22.4) 65 (19.6) 0.69 21 (27.6) 0.57
Liver cirrhosis 5 (6.6) 45 (13.6) 0.12 10 (13.2) 0.28
Chronic renal failure 10 (13.2) 35 (10.5) 0.54 18 (23.7) 0.14
Malignancy 4 (5.3) 33 (9.9) 0.27 18 (23.7) < 0.01
Biliary tract diseases 2 (2.6) 20 (6.0) 0.39 8 (10.5) 0.10
Absence of underlying diseases 12 (15.8) 44 (13.3) 0.69 9 (11.8) 0.64
Therapy in the month prior to the infection
Proton-pump inhibitors 8 (10.5) 24 (7.2) 0.47 15 (19.7) 0.17
Aspirin 2 (2.6) 56 (16.9) < 0.01* 8 (10.5) 0.10
Antibiotics 5 (6.6) 28 (8.4) 0.76 12 (15.8) 0.12
+Age-matched analysis (K. pneumoniae invasive syndrome vs. control group).
*Results of multivariate analysis indicated that community-acquired K. pneumoniae bacteremic patients who were infected by strains expressing the hypermucov-
iscosity phenotype (odds ratio [OR], 31.07; 95% confidence interval [CI], 13.55-71.22; p < 0.01) and diabetic patients with poor glycemic control (OR, 2.46; 95% CI,
1.27-4.77; p < 0.01) were at increased risk, whereas those who had recent therapy with aspirin (OR, 0.17; 95% CI, 0.04-0.79; p = 0.02) were at lower risk of acquiring
K. pneumoniae-associated invasive syndrome.
Figure 1 Effects of sodium salicylate (SAL) on live KP-M1 strain
of Klebsiella pneumoniae. After 24-h incubation with various
concentrations of SAL, the growth of KP-M1 cells were monitored by
reading the absorbance (OD) at 490 nm. The growth of KP-M1 cells
cultured in media containing 10 or 30 μg/mL SAL did not differ from
those cultured without SAL. However, the KP-M1 cells decreased
in growth when the bacteria were cultured in the presence of
300 μg/mL SAL.
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Discussion
The CPS surrounding KP bacteria enables the bacteria
to evade phagocytosis [23,24]. Reduction of the CPS by
SAL may therefore attenuate the pathogenicity of KP
strains. Cell death could not explain the decrease in CPS
observed in our experiments because viable bacterial
colonies remained unchanged in the presence of various
levels of SAL that were optimized for reducing the CPS.
These levels of SAL are within the therapeutic range
measured in serum after ingestion of low dose aspirin
[25]. Hence, with the common oral use of aspirin, the
effect of CPS reduction in KP could occur.
Epidemiological studies have demonstrated that the ma-
jority of KP infections are preceded by the colonization of
the gastrointestinal tract [26]. Patients infected with HV-
KP strains and DM patients with uncontrolled glycemia
are known to be at increased risks for invasive syndrome
[3,17]. Our results indicated that patients who had used
aspirin during the month prior to the diagnosis of
community-acquired KP bacteremia appeared to be
associated with a lower risk for invasive syndrome.
The mechanism by which CPS is reduced in the pres-
ence of SAL remains unclear. Metal ions are cofactors
for some of the enzymes involved in polysaccharide syn-
thesis [27]. SAL has been identified as the biosynthetic
precursor of the aromatic ring in pyochelin, an iron-
chelating siderophore [28]. Divalent cations also play an
important role in the stabilization of bacterial outer-
membrane proteins [28]. The reduction of CPS production
by SAL is likely the result of either the modulation of en-
zyme activity in CPS synthesis pathways or the disruption
of the functional integrity of KP outer membranes.
Neutrophils have been shown to be capable of ingest-
ing and killing encapsulated KP in the presence of com-
plement [23]. SAL-mediated capsular suppression was
shown to enable serum complement, such as C3, to bind
to sites on the bacteria that were otherwise masked by
the capsule [10]. In our experiments, homogenization
with SAL removed 20% to 40% of the CPS production
and resulted in approximately 40% to 60% increase in
the rate of phagocytosis. Although homogenization with
low doses of aspirin did not completely remove the
Figure 2 String test for hypermucoviscosity (HV) in the KP-M1 strain of Klebsiella pneumoniae. (A) Each closed bar indicates the mean ±
standard deviation in millimeters for the results of string tests among KP-M1 organisms treated with various concentrations of sodium salicylate (SAL)
as indicated. The asterisk indicates the significant changes among the results with different SAL concentrations (p < 0.01). (B) Representative
photographs of the stretched, mucoviscous string from single colonies of KP-M1 organisms treated with various concentrations of SAL
as indicated.
Figure 3 Flow cytometry assessment of neutrophil phagocytosis. (A) Trypan blue quenching of the extracellular fluorescence of bound
bacteria and phagocytosed bacteria by neutrophils after incubation at 37°C for 60 min were evaluated by flow cytometry. (B) The KP-M1 bacteria
were significantly more susceptible to phagocytosis by neutrophils after incubation with 10 or 30 μg/mL sodium salicylate (SAL).
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capsule, it may render the bacteria to become more sus-
ceptible to phagocytosis by neutrophils. The loss of cap-
sular materials may help to expose the cell surface of KP
to the host defense mechanisms and thus shorten the
time required for the clearance of the infection [29].
Recently, aspirin was shown to promote the killing of
S. pneumoniae by blood leukocytes through COX inhib-
ition [13]. Similarly, in the present study, we further
demonstrated that aspirin enhanced the killing of HV-
KP by leukocytes. However, the survival rates of KP-M1
cells did not have significant changes whether or not the
bacteria were pretreated with SAL. KP organisms have
been shown to remain alive after being phagocytosed
[6]. Therefore, SAL treatment may only increase the up-
take of the bacteria by neutrophils without affecting the
extent of neutrophil-mediated intracellular killing. It is
until the addition of aspirin-pretreated leukocytes that
an enhance leukocyte bactericidal effect is observed.
Although the multivariate analysis showed significant
protection in patients who were treated with aspirin,
their blood levels of SAL were not documented. In
addition, we did not perform stool sampling for KP iso-
lation, and so the contribution of aspirin to patients’ car-
riage could not be assessed. It was an uncontrolled
observational study. The patients who suffered from KP
bacteremia may be severe and referred from other hospi-
tals, the reliability of medication history may be a con-
founding factor. Therefore, we could not exclude the
possibilities of other unmeasured potential confounders
that may affect the association of aspirin with the en-
hanced leukocyte killing, thus limiting our ability to
delineate the true relationship between aspirin and in-
vasive HV-KP infection. Lastly, only one strain (KP-
M1; serotype K1) was assessed in this study. However,
epidemiological reports have indicated that capsular
serotype K1 is the most prevalent in primary KP liver
abscess [2,7]. Serotype K1 strains were also signifi-
cantly more virulent than non-K1 strains, in terms of
higher in vitro serum resistance and greater risk of sep-
tic ocular or central nervous system complications for
primary liver abscess.7 Therefore, our results derived
from the representative serotype K1 strain might be
extrapolated for the majority of KP strains that caused
invasive syndrome.
Conclusions
In summary, our data indicated that SAL could affect
the CPS production and the HV phenotype in KP. It also
Figure 4 Ex vivo human leukocyte bactericidal activity assay. Human peripheral white blood cells (WBCs) from 5 healthy males were
collected before and one hour after oral administration of 100 mg of aspirin (ASA), and incubated, respectively, with the KP-M1 strain of Klebsiella
pneumoniae (KP) which had been previously opsonized with normal human serum. The ASA treatment significantly enhanced the leukocyte
killing of KP-M1 (p < 0.01), disregard whether or not the KP-M1 organisms were pre-incubated with sodium salicylate (SAL, 30 μg/mL).
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promotes the leukocyte phagocytosis and bactericidal
activity against KP. The in vitro and ex vivo effects of
SAL on serotype K1 KP warrant further investigation on
the role of aspirin as an adjunct therapy for KP-mediated
invasive syndrome.
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